v3.26.1
Document and Entity Information - USD ($)
 12 Months Ended
Mar. 31, 2026
Jul. 10, 2026
Sep. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Mar. 31, 2026    
Document Fiscal Year Focus 2026    
Document Fiscal Period Focus FY    
Trading Symbol VIVS    
Entity Registrant Name VIVOSIM LABS, INC.    
Entity Central Index Key 0001497253    
Current Fiscal Year End Date --03-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   3,494,071  
Entity Public Float     $ 7,538,844
Entity File Number 001-35996    
Entity Tax Identification Number 27-1488943    
Entity Address, Address Line One 11555 Sorrento Valley Rd    
Entity Address, Address Line Two Suite 100    
Entity Address, City or Town San Diego    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92121    
City Area Code 858    
Local Phone Number 224-1000    
Document Annual Report true    
Document Transition Report false    
Entity Interactive Data Current Yes    
Document Financial Statement Error Correction [Flag] false    
Entity Incorporation, State or Country Code DE    
Security Exchange Name NASDAQ    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Auditor Name Rosenberg Rich Baker Berman, P.A.    
Auditor Firm ID 89    
Auditor Location Somerset, New Jersey    
Auditor Opinion [Text Block]

We have audited the accompanying consolidated balance sheets of VivoSim Labs, Inc., formerly known as Organovo Holdings, Inc., (the “Company”) as of March 31, 2026 and 2025, and the related statements of operations and other comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two-year period ended March 31, 2026, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2026 and 2025, and the results of its operations and its cash flows for each of the years in the two-year period ended March 31, 2026, in conformity with accounting principles generally accepted in the United States of America.